Objectives:
This study aimed to understand the complex relationship between type-2 diabetes mellitus (T2DM) management and cancer, ultimately improving patient care and informing public health.
Methods:
This observational cohort study utilized data from the National Institutes of Health Survey (NIHS) for the years 2022 and 2023, comparing health characteristics, risk factors, and cancer risks between patients with T2DM and healthy controls. Data analysis involved multivariate logistic regression to examine associations between T2DM, its treatments, and the incidence of various cancers, adjusting for confounders such as age, gender, hypertension, and smoking status.
Results:
The findings indicated that T2DM significantly elevated the risk of several cancers, notably pancreatic (OR=24.913), liver, uterine, and rectal cancers. Lifestyle factors such as smoking and electronic cigarette use also showed strong associations with increased cancer risks in diabetic patients. Treatments including diabetic pills and insulin were particularly linked with varying cancer risks, highlighting the complex interactions between diabetes management and cancer development.
Conclusions:
The study underscored a critical need for comprehensive diabetes management that extended beyond glycemic control to potentially include cancer risk monitoring. These results suggested that the interplay between diabetes treatments and long-term cancer risks warrants further investigation to optimize treatment strategies and improve overall patient outcomes in individuals with T2DM.
Key words: Type 2 diabetes mellitus, cancer risk, diabetic complications, lifestyle factors, diabetes treatments.
|
